Previous research indicates that PSA screening has the potential of overdiagnosing patients and increasing prostate cancer incidence among men more likely to die from other causes before prostate cancer symptoms manifest themselves [4–8, 24]. This evidence concerns the gene KLK3 and prostate cancer.